E
BioVie Inc. BIVI
$1.22 -$0.03-2.40% NASDAQ
Recommendation
Prev Close
$1.22
Volume
87,659
Avg Vol (90D)
123,528
Market Cap
$9.20M
Dividend & Yield
--
52-Week Range
$1.10 - $20.40
P/E (TTM)
--
EPS (TTM)
-$8.97
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
BioVie hits enrolment milestone in early Parkinson's trial, data due later this year
1/16/2026 - Proactive Investors - UK
BioVie completes enrollment in Phase 2 SUNRISE-PD trial
1/8/2026 - The Fly
BioVie Completes Enrollment in Phase 2 SUNRISE-PD Trial in Early Parkinson's Disease
1/8/2026 - GuruFocus
BioVie Completes Enrollment in Phase 2 SUNRISE-PD Trial in Early Parkinson's Disease
1/8/2026 - Globe Newswire
BioVie (NASDAQ:BIVI) Trading Down 5.8% - What's Next?
12/25/2025 - Ticker Report
HALPER SADEH LLC ENCOURAGES BIOVIE INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS
12/24/2025 - GuruFocus
HALPER SADEH LLC ENCOURAGES BIOVIE INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS
12/24/2025 - PR Newswire
BioVie advances lead drug candidates - ICYMI
12/20/2025 - Proactive Investors - UK
BioVie advances Parkinson's, long COVID, and liver disease programs ahead of 2026
12/17/2025 - Proactive Investors - UK
What Makes BioVie (BIVI) a New Buy Stock
12/11/2025 - Zacks Investment Research
BioVie Inc. (BIVI) Discusses Clinical Progress of Lead Drug Candidates Targeting Parkinson's, Alzheimer's, and Liver Disease Transcript
12/10/2025 - Seeking Alpha: Transcripts
BioVie Inc. (BIVI) Discusses Clinical Progress of Lead Drug Candidates Targeting Parkinson's, Alzheimer's, and Liver Disease Transcript
12/10/2025 - SeekingAlpha
BioVie Inc. (BIVI) Discusses Clinical Progress of Lead Drug Candidates Targeting Parkinson's, Alzheimer's, and Liver Disease - Slideshow
12/10/2025 - SeekingAlpha
Join Biovie's Exclusive Live Investor Webinar and Q&A Session on December 9
11/19/2025 - GuruFocus
Join Biovie's Exclusive Live Investor Webinar and Q&A Session on December 9
11/19/2025 - Globe Newswire
BioVie Stockholders Approve Key Proposals at Annual Meeting
11/12/2025 - TipRanks Financial Blog
BioVie (NASDAQ:BIVI) Issues Quarterly Earnings Results
11/12/2025 - Ticker Report
Halper Sadeh LLC Encourages BioVie Inc. Shareholders to Contact the Firm to Discuss Their Rights
10/24/2025 - GuruFocus
Halper Sadeh LLC Encourages BioVie Inc. Shareholders to Contact the Firm to Discuss Their Rights
10/24/2025 - Business Wire
BIOVIE ALERT: Bragar Eagel & Squire, P.C. is Investigating BioVie Inc. ...
10/9/2025 - GuruFocus
BIOVIE ALERT: Bragar Eagel & Squire, P.C. is Investigating BioVie Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
10/9/2025 - Globe Newswire
BioVie Inc. - Special Call
10/8/2025 - SeekingAlpha
BioVie Inc. (BIVI) Discusses Latest Clinical Advancements, Investment Potential, And Upcoming Data Readouts Transcript
10/8/2025 - Seeking Alpha: Transcripts
BioVie Inc. - Special Call
10/8/2025 - Seeking Alpha: Transcripts
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
-$19.00M
EBIT (TTM)
-$19.23M
Net Income (TTM)
-$18.48M
Balance Sheet
Total Assets (Q)
$26.82M
Total Debt (Q)
$332.70K
Total Liabilities (Q)
$1.90M
Book Value Per Share (Q)
$3.31
Cash Flow
Cash from Operations (TTM)
-$18.47M
Cash from Investing (TTM)
--
Cash from Financing (TTM)
$23.42M
Net Change in Cash (TTM)
$4.95M
Filings
Filing Date
Monday, November 10, 2025
Period Date
Tuesday, September 30, 2025
Next Filing
Week of Feb 9 and 13 (est)
Price History
Loading...
Beta
1.18
7-Day Total Return
0.83%
30-Day Total Return
-22.78%
60-Day Total Return
-34.41%
90-Day Total Return
-33.52%
Year to Date Total Return
-8.27%
1-Year Total Return
-93.68%
2-Year Total Return
-98.66%
3-Year Total Return
-99.77%
5-Year Total Return
-99.96%
52-week Low
Dec 30, 2025 - $1.10
52-week High
Feb 05, 2025 - $20.40
Valuation
Market Cap
$9.20M - Nano Cap
Enterprise Value
-$15.45M
Price/Sales (TTM)
--
Price/Book (Q)
0.37
Dividends and Shares
Shares Outstanding
5.21M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
bioviepharma.com
Phone Number
775 888 3162
Address
680 W. Nye Lane
Carson City, NV 89703
Country
United States
Year Founded
2013
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The... more
NASDAQ 01/23/2026 4:00PM Eastern Quotes delayed